1506TiPPhase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC. (23rd October 2018) - Planchard, D; Janne, P A; Yu, H A; Moro-Sibilot, D; Goldberg, T; Gu, X; Li, J; McGill, J; Yu, C; Slosberg, E